AB0525 ANTI-SMITH ANTIBODY IS ASSOCIATED WITH DISEASE ACTIVITY IN PATIENTS WITH NEW-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019)

• Record Type: Journal Article
• Authors: Jung, Seungmin; Yoo, Juyoung; Ahn, Sungsoo; Lee, Sangwon; Song, Jason Jungsik; Park, Yongbeom
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1724
• Page End: 1725
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.7016
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Anti-Smith (Sm) antibody is a highly specific antibody for systemic lupus erythematosus (SLE). Despite the remarkable specificity of anti-Sm antibodies for SLE, the association between anti-Sm antibody level and the clinical manifestation of SLE is still unclear. Objectives: We aimed to evaluate the association between anti-Sm antibodies and disease activity in patients with new-onset SLE. Methods: We included patients who were repeatedly tested for anti-Sm antibodies at SLE diagnosis and within 12 months after SLE diagnosis. The clinical and laboratory profiles, and SLE disease activity index (SLEDAI) were collected at the time of the anti-Sm antibody test. SLEDAI and laboratory variables associated with disease activity were compared at baseline between patients with and without anti-Sm antibodies. The longitudinal association between disease activity and anti-Sm antibodies was also evaluated in total patients and in those with anti-Sm antibodies. Results: Of 92 patients who were tested for anti-Sm antibodies at the time of SLE diagnosis, 67 and another 67 patients were followed up for the presence of anti-Sm antibodies at 6 and 12 months, respectively. Although the baseline SLEDAI was comparable in SLE patients with and without anti-Sm antibodies, the serum anti-Sm antibody level at diagnosis was significantly correlated with SLEDAI ( P = 0.003). Patients with anti-Sm antibodies at 12 months had higher SLEDAI and anti-dsDNA levels than those without anti-Sm antibodies ( P = 0.002, respectively). The changes in anti-Sm antibody levels over 12 months were also correlated with the alterations in SLEDAI (P = 0.029). Conclusion: This study suggests that anti-Sm antibody level is associated with disease activity in patients with new-onset SLE, and that monitoring of anti-Sm antibody levels could help assess the disease activity. References: [1] Migliorini, P., et al., Anti-Sm and anti-RNP antibodies. Autoimmunity, 2005. 38(1): p. 47-54. [2] Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol, 2015. 34(7): p. 1217-23. [3] What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol, 2017. 35(4): p. 598-606. Disclosure of Interests: None declared